Emerging insights to lung cancer drug resistance

Abstract

Lung cancer remains the malignant tumor with the highest morbidity and mortality in China, with non-small cell lung cancer (NSCLC) accounting for 80%-85% of cases. Nowadays, the treatment pattern of NSCLC has evolved toward precision management with the development of molecular targeted therapy and immunotherapy. However, the median overall survival for patients with metastatic NSCLC, unfortunately, remains less than three years. Drug resistance is the bottleneck to preventing drugs from playing a further role, and the mechanistic study of drug resistance is the prerequisite for new regimen development. This Special Issue pays special attention to drug resistance in the treatment of NSCLC. We received and published several excellent articles regarding this topic. We hope that, through this Special Issue, we can have a deep understanding of the existing problems, the underlying mechanism, and the future solutions and that the publication of this Special Issue can bring some inspiration to readers.

Keywords

Non-small cell lung cancer / drug resistance / targeted therapy / immunotherapy

References

[1] Chen W,Zuo T,Zhang S.National cancer incidence and mortality in China, 2012.Chin J Cancer Res2016;28:1-11 PMCID:PMC4779764

[2] Molina JR,Cassivi SD,Adjei AA.Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.Mayo Clin Proc2008;83:584-94 PMCID:PMC2718421

[3] Herbst RS,Boshoff C.The biology and management of non-small cell lung cancer.Nature2018;553:446-54

[4] Wang M,Boshoff C.Toward personalized treatment approaches for non-small-cell lung cancer.Nat Med2021;27:1345-56

[5] Mitsudomi T,Yatabe Y.Surgery for NSCLC in the era of personalized medicine.Nat Rev Clin Oncol2013;10:235-44

[6] Tripathi SK,Rengasamy KRR.Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.Med Res Rev2020;40:2132-76

[7] Schoenfeld AJ.The evolving landscape of resistance to osimertinib.J Thorac Oncol2020;15:18-21

[8] Schoenfeld AJ,Kubota D.Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer.Clin Cancer Res2020;26:2654-63 PMCID:PMC7448565

[9] Kashima Y,Suzuki A.Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer.Cancer Res2021;81:4835-48 PMCID:PMC8448980

[10] Nilsson MB,Robichaux J.A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.Sci Transl Med2020;12:eaaz4589 PMCID:PMC8269000

[11] Sun Y,Czako B.Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib.Cancer Res2020;80:4840-53

[12] Okura N,Yamada T.ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in.EGFR26:2244-56

[13] Zhu L,Zang H.Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third-generation EGFR tyrosine kinase inhibitor, osimertinib.Cancer Res2021;81:4822-34 PMCID:PMC8448971

[14] Prior IA,Hartley JL.The frequency of ras mutations in cancer.Cancer Res2020;80:2969-74 PMCID:PMC7367715

[15] Ostrem JM,Sos ML,Shokat KM.K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.Nature2013;503:548-51 PMCID:PMC4274051

[16] Skoulidis F,Dy GK.Sotorasib for lung cancers with KRAS p.G12C mutation.N Engl J Med2021;384:2371-81 PMCID:PMC9116274

[17] Ou SI,Leal TA.First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced.KRASG12C:JCO2102752

[18] Awad MM,Rybkin II.Acquired resistance to KRAS^G12C inhibition in cancer.N Engl J Med2021;384:2382-93 PMCID:PMC8864540

[19] Koga T,Fujino T.KRAS Secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments.J Thorac Oncol2021;16:1321-32

[20] Zhao Y,Xue JY.Diverse alterations associated with resistance to KRAS(G12C) inhibition.Nature2021;599:679-83 PMCID:PMC8887821

[21] Akhave NS,Hong DS.Mechanisms of resistance to KRAS^G12C-targeted therapy.Cancer Discov2021;11:1345-52 PMCID:PMC8178176

[22] Canon J,Saiki AY.The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.Nature2019;575:217-23

[23] Kluger HM,Ascierto ML.Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce.J Immunother Cancer2020;8:e000398 PMCID:PMC7174063

[24] Chen DS.Oncology meets immunology: the cancer-immunity cycle.Immunity2013;39:1-10

[25] Peng W,Liu C.Loss of PTEN promotes resistance to T cell-mediated immunotherapy.Cancer Discov2016;6:202-16 PMCID:PMC4744499

[26] Pore N,Standifer N.Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in patients with non-small cell lung cancer and is reversed by STAT3 knockdown.Cancer Discov2021;11:2828-45

[27] Spranger S.Impact of oncogenic pathways on evasion of antitumour immune responses.Nat Rev Cancer2018;18:139-47 PMCID:PMC6685071

[28] Li R,Crosson W.Inhibition of granulocytic myeloid-derived suppressor cells overcomes resistance to immune checkpoint inhibition in LKB1-deficient non-small cell lung cancer.Cancer Res2021;81:3295-308 PMCID:PMC8776246

[29] Yang Z,Wang B.USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade.Nat Commun2021;12:4852 PMCID:PMC8357983

[30] Wennerberg E,Spada S.Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer.Sci Transl Med2022;14:eabe8195

[31] Ren S,You H,Zhou P.The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer.Front Immunol2021;12:689132 PMCID:PMC8206805

[32] Zhang H,Zhu L,Ma S.Cancer-associated fibroblasts in non-small cell lung cancer: recent advances and future perspectives.Cancer Lett2021;514:38-47

[33] Horton BL,Momin N.Lack of CD8⁺ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer.Sci Immunol2021;6:eabi8800

[34] Schoenfeld AJ.Acquired resistance to immune checkpoint inhibitors.Cancer Cell2020;37:443-55 PMCID:PMC7182070

[35] Anagnostou V,Forde PM.Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer.Cancer Discov2017;7:264-76 PMCID:PMC5733805

[36] Qin S,Yi M,Wu K.Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.Mol Cancer2019;18:155 PMCID:PMC6833286

[37] Chen L,Yang Y.CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade.Cancer Discov2018;8:1156-75 PMCID:PMC6205194

[38] Peixoto P,Boyer-guittaut M.Epigenetics, a key player of immunotherapy resistance.Cancer Drug Resist2018;1:219-29

[39] Wu J,Zhang P.Tumor-derived exosomes: immune properties and clinical application in lung cancer.Cancer Drug Resist2022;5:102-13 PMCID:PMC8992595

[40] Li Y,Peng X,Tang B.Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer.Cancer Drug Resist2022;5:129-46 PMCID:PMC8992585

[41] Yu X,Wu Y.Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer.Cancer Drug Resist2021;4:728-39 PMCID:PMC9086517